Bradykinin inhibits serum-depletion-induced apoptosis of human vascular endothelial cells by inducing nitric oxide via calcium ion kinetics.
Vascular endothelial cells play important roles in atherogenesis, and bradykinin is associated with atherosclerosis. The effect of bradykinin on apoptosis in human umbilical vein endothelial cells (HUVECs) was investigated, with a focus on Ca2+ kinetics and nitric oxide production. In serum-free conditions, the number of apoptotic cells increased in a time-dependent manner, but this increase was inhibited by bradykinin in a dose-dependent manner. The apoptosis inhibited by bradykinin was reduced by nitric oxide inhibitor N(G)-monomethyl-L-arginine (L-NMMA) and consequently restored by combined treatment with L-NMMA and L-arginine. Bradykinin increased influx of extracellular Ca2+, generation of inositol 1,4,5-trisphosphate, and release of Ca2+ from intracellular storage sites, thus increasing the total intracellular Ca2+ concentration ([Ca2+]i). Bradykinin increased nitric oxide production, which was inhibited by L-NMMA and restored by combined treatment with L-NMMA and L-arginine. Sodium nitroprusside (SNP) dose-dependently increased nitric oxide production and inhibited apoptosis; however, 10(-5) M SNP did not inhibit apoptosis. Caspase-3 inhibitor, acetyl-Asp-Met-Gln-Asp-aldehyde, enhanced bradykinin-induced inhibition of apoptosis but did not effect bradykinin-induced nitric oxide production. These findings suggest that bradykinin inhibits serum-depletion-induced apoptosis in HUVECs by enhancing nitric oxide production via an increase in [Ca2+]i.
Kono
Yoshihito
Y
Second Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. sawada@koto.kpu-m.ac.jp
Sawada
Shohei
S
Kawahara
Takeshi
T
Tsuda
Yutaka
Y
Higaki
Tadashi
T
Yamasaki
Seiki
S
Imamura
Hitoshi
H
Tada
Yusuke
Y
Sato
Toshiyuki
T
Hiranuma
Osamu
O
Akamatsu
Naoaki
N
Komatsu
Sumio
S
Tamagaki
Toshiyuki
T
Nakagawa
Katsumi
K
Tsuji
Hajime
H
Nakagawa
Masao
M
D017209:Apoptosis / Q000187:drug effects*; D001920:Bradykinin / Q000494:pharmacology* / Q000502:physiology; D002118:Calcium / Q000378:metabolism* / Q000502:physiology; D053148:Caspase 3; D061945:Caspase Inhibitors; D002413:Cations, Divalent; D002478:Cells, Cultured; D016895:Culture Media, Serum-Free; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D015544:Inositol 1,4,5-Trisphosphate / Q000378:metabolism; D007424:Intracellular Fluid / Q000378:metabolism; D009569:Nitric Oxide / Q000096:biosynthesis* / Q000502:physiology; D020030:Nitric Oxide Donors / Q000494:pharmacology; D009599:Nitroprusside / Q000494:pharmacology; D009842:Oligopeptides / Q000494:pharmacology; D014471:Umbilical Veins / Q000166:cytology / Q000378:metabolism
D061945:Caspase Inhibitors; D002413:Cations, Divalent; D016895:Culture Media, Serum-Free; D015853:Cysteine Proteinase Inhibitors; D020030:Nitric Oxide Donors; D009842:Oligopeptides; C110922:acetyl-aspartyl-methionyl-glutaminyl-aspartyl-aldehyde; D009599:Nitroprusside; D009569:Nitric Oxide; D015544:Inositol 1,4,5-Trisphosphate; C505407:CASP3 protein, human; D053148:Caspase 3; D001920:Bradykinin; D002118:Calcium